|Day Low/High||198.01 / 203.62|
|52 Wk Low/High||166.30 / 211.90|
Jefferies raises its price target for AMGN and judgement day looms for JNJ; here's our take on the health of both companies.
Jim discusses an Amgen price target boost, previews tonight's earnings release from Salesforce.com, and talks Viacom!
Study Evaluated Efficacy and Safety of ABP 798 Compared to Rituxan in Patients With Non-Hodgkin's Lymphoma
Amgen's rating is lowered at Mizuho but its price target gets raised to $212.
Markets were whipsawed this week by trade-war jitters and the U.S yield-curve inversion.
Jeff fills in for Jim to discuss Nvidia's earnings, analyst activity around Burlington Stores, and more!
Understanding yourself and the investing environment you are in are keys to avoiding panic brought on by fear.
2019 has been a banner year for professional golf, and a profitable one for these top linksters.
Amgen's patents for Enbrel likely to be protected until 2029.
Jim discusses this morning's profit-taking cash raising effort, Amgen's successful defense of Enbrel, semiconductors, and more!
We are staying the course, using bouts of panic to buy up the stocks of high-quality companies on discounts.
Court Upholds Validity of Patent Claims Directed to Enbrel
These companies already posted strong earnings this season and are not economically sensitive.
In July, the RMPIA climbed 0.6%, bringing its year-to-date return to just over 21%.
We are taking a moment to provide price levels for nearly every position in the portfolio.
Amgen built on the momentum at a recent conference on its Q2 earnings call as management highlighted recent positive developments for its KRAS inhibitor drug.
While the trade war is clearly intensifying, we are viewing the market through a buyers' lens, waiting for pullbacks that improve our basis.
Amgen shares are up the day after it reported results, but not all analysts are cheering with abandon.
U.S. stock futures rise, getting a lift from Apple, which was higher after the tech giant beat earnings expectations, and as Wall Street prepares for the first interest rate cut from the Federal Reserve in more than a decade; GE, Qualcomm and Humana report earnings.
Here we break down the numbers of some of the company's top drugs, but we now only have 175 shares remaining in this tag end of a position, as there are better health care stocks in the market right now.
THOUSAND OAKS, Calif., July 30, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced financial results for the second quarter of 2019.
Portfolio names Lam Research and Twilio report Wednesday, Dupont and Shopify on Thursday.
Jim discusses earnings from BP and Mastercard, previews tonight's earnings from Apple and Amgen, and more!
Overall, expect trading volume, with notable exception of action in specific names reporting earnings, to remain on the light side right through later Wednesday afternoon.
U.S. stock futures point lower on Tuesday, the first day of a critical two-day meeting of the Federal Reserve, and ahead of quarterly earnings from tech giant Apple; the earnings calendar also includes reports from Merck, Procter & Gamble, Mastercard and AMD; Capital One says a hacker got access to the personal information of more than 100 million of its credit card customers and applicants.
Portfolio names Mastercard, BP, Apple and Amgen will report quarterly results Tuesday.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.